首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal CD307E Antibody

  • 中文名: CD307E抗体
  • 别    名: FCRL5; CD307; FCRH5; IRTA2; BXMAS1; PRO820
货号: IPD31621
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

AliasesFCRL5; CD307; FCRH5; IRTA2; BXMAS1; PRO820
Entrez GeneID83416
clone2A10D6
WB Predicted band size106.4kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD307E (AA: extra 16-158) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

参考文献

以下是关于CD307E(FcRL5)抗体的3篇参考文献及其摘要概括:

1. **"FcRL5: A novel target for antibody-based therapy in B-cell malignancies"**

- **作者**: Smith A, et al.

- **摘要**: 本研究探讨了CD307E(FcRL5)在B细胞恶性肿瘤中的表达及其作为治疗靶点的潜力。作者开发了一种人源化单克隆抗体,证明其可通过抗体依赖性细胞毒性(ADCC)和抑制B细胞受体信号通路,显著抑制小鼠模型中淋巴瘤的生长。

2. **"Structural insights into Fc receptor-like 5 (FcRL5) and its interaction with antigens"**

- **作者**: Johnson R, et al.

- **摘要**: 通过X射线晶体学解析了CD307E的胞外域结构,揭示了其独特的抗原结合机制。研究还发现,针对特定表位的抗体可阻断CD307E与自身抗原的结合,为治疗自身免疫性疾病(如类风湿关节炎)提供了新思路。

3. **"CD307E regulates B-cell tolerance and its antibody-mediated modulation suppresses lupus nephritis"**

- **作者**: Wang Y, et al.

- **摘要**: 在系统性红斑狼疮(SLE)小鼠模型中,抗CD307E抗体通过调节B细胞活化和自身抗体产生,显著减轻肾脏损伤。研究强调了靶向CD307E在自身免疫疾病治疗中的临床价值。

注:以上文献信息为示例,实际研究中请通过PubMed或Google Scholar以“CD307E”、“FcRL5”或“Fc receptor-like 5”为关键词检索最新论文。部分研究可能需关注其与B细胞功能、肿瘤免疫治疗或自身免疫疾病的关联。

背景信息

CD307e antibody targets the CD307e antigen, also known as Fc receptor-like 5 (FcRL5) or IRTA2. a transmembrane glycoprotein predominantly expressed on B cells. As part of the Fc receptor-like (FCRL) family, CD307e features extracellular immunoglobulin domains and cytoplasmic signaling motifs, enabling interactions with immune complexes and modulation of B cell receptor (BCR) signaling. Unlike classical Fc receptors, FCRL members like CD307e lack direct binding to IgG but regulate B cell activation, differentiation, and tolerance. CD307e is notably upregulated in certain B cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma, and is linked to autoimmune disorders like systemic lupus erythematosus (SLE). Its restricted expression on B lineage cells and involvement in pathological conditions make CD307e a promising therapeutic target. Antibodies against CD307e are being explored for diagnostic applications, targeted drug delivery, and immunomodulatory therapies, including antibody-drug conjugates (ADCs) or bispecific antibodies. Research continues to clarify its precise biological roles and potential in precision medicine for B cell-related diseases.

客户数据及评论

折叠内容

大包装询价

×